HLA-A||440.79 Human leukocyte antigen||259.75 Blood type||251.88 HLA-DQ8||244.01 HLA DR3-DQ2||228.26 Immune system||212.52 ABO blood group system||204.65 Adaptive immune system||181.04 Oncoantigen||161.62 Cd4+ T cells and antitumor Immunity||149.55 HLA-A33||141.68 Polyclonal antibodies||141.68 Polyclonal B cell response||118.07 Central tolerance||110.19 HLA-DR||110.19 HLA-A68||102.32 Tumor antigen||94.45 Immune tolerance||94.45 Human blood group systems||94.45 Autoimmunity||86.58 Rhesus blood group system||86.58 Other red cell antigens||86.58 HLA-A69||78.71 Malaria vaccine||78.71 Antigen presentation||78.71 Immune privilege||78.71 Kell antigen system||70.84 Molecular mimicry||70.84 Cancer immunotherapy||62.97 Kauffman-White classification||62.97 RHCE (gene)||55.09 Cross-presentation||55.09 B cell||55.09 Yersinia pestis||55.09 HLA-DP||55.09 QuantiFERON||55.09 Human platelet antigen||55.09 MNS antigen system||55.09 T cell||47.22 Immunotherapy||47.22 Salmonella||47.22 CD74||47.22 Major histocompatibility complex||47.22 Γδ T cells||47.22 Ouchterlony double immuno diffusion||39.35 Serotype||39.35 KIR3DL3||39.35 Anti-neutrophil cytoplasmic antibody||39.35 HLA-A3||39.35